MannKind (MNKD) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues reached $78.4M, up 18% year-over-year, with net income of $13.2M, a 24% increase, and non-GAAP net income of $22M, up 43% year-over-year.

• Growth was driven by Afrezza NRx (+20%) and TRx (+14%), and substantial Tyvaso DPI royalties and manufacturing revenue.

• Cash, cash equivalents, and investments totaled $198M as of March 31, 2025, supporting ongoing operations and R&D.

• Pipeline progress includes Afrezza pediatric sBLA submission expected mid-2025, MNKD-101 Phase 3 enrollment on track, and MNKD-201 to advance in 2H 2025.

• Continued focus on commercializing Afrezza and V-Go, and advancing pipeline assets MNKD-101 and MNKD-201.

Financial highlights

• Total revenues grew 18% to $78.4M, with Tyvaso DPI royalties up 32% to $30M and manufacturing revenue up 18% to $29M.

• Net income was $13.2M ($0.04 EPS), up from $10.6M in Q1 2024; non-GAAP net income was $22M ($0.07 EPS), up 43% year-over-year.

• Afrezza net revenue was $15M, up 3% year-over-year; V-Go net revenue declined 6% to $4M.

• Gross margin on commercial products held steady at 80% year-over-year.

• Operating expenses increased 13% to $56.1M, driven by higher R&D and SG&A costs.

Outlook and guidance

• Anticipates continued royalty revenue growth from Tyvaso DPI and a change in Afrezza's growth trajectory, especially with potential pediatric approval.

• Afrezza pediatric sBLA filing planned for mid-2025; topline pediatric data expected 2Q 2025.

• MNKD-101 Phase 3 trial aims for 100-patient interim enrollment by year-end 2025; MNKD-201 to advance in 2H 2025.

• Sufficient liquidity to fund operations for at least the next 12 months, with $198M in capital resources.

• Every 10,000 insured Tyvaso DPI patients could yield $300M–$350M in revenue; every 10% pediatric share in Afrezza could add $150M in net revenue.